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Introduction {#pds4041-sec-0005}
============

Legislation has been introduced to stimulate the conduct of clinical trials in children,[1](#pds4041-bib-0001){ref-type="ref"}, [2](#pds4041-bib-0002){ref-type="ref"}, [3](#pds4041-bib-0003){ref-type="ref"} leading to more evidence on efficacy of new drugs or new formulations of existing drugs in children.[4](#pds4041-bib-0004){ref-type="ref"} This laudable action has greatly improved the evidence for new drugs but does not impact much on the available safety data because information on rare and potentially more serious safety issues cannot be obtained from randomized clinical trials (RCTs).[5](#pds4041-bib-0005){ref-type="ref"}, [6](#pds4041-bib-0006){ref-type="ref"}

Safety data can be generated more efficiently from postmarketing observational studies,[7](#pds4041-bib-0007){ref-type="ref"}, [8](#pds4041-bib-0008){ref-type="ref"} particularly relevant in children among whom the use of drugs is high and frequently off‐label but recorded in routine care records.[9](#pds4041-bib-0009){ref-type="ref"} The availability of large scale healthcare and claims databases provides an outstanding opportunity to perform safety studies. However, because the studies are observational, their design requires extra attention to avoid misclassification and address potential confounding. Although the field of pharmacoepidemiology has grown substantially in the last 20 years, very few researchers focus on pediatrics.

As part of the Global Research in Paediatrics---Network of Excellence ([http://www.grip‐network.org](http://www.grip-network.org)/), we conducted a systematic review of the medical literature in order to assess the characteristics of pharmacoepidemiological studies evaluating the safety of drugs in children.

Methods {#pds4041-sec-0006}
=======

Search strategy {#pds4041-sec-0007}
---------------

We conducted this review according to PRISMA guidelines.[10](#pds4041-bib-0010){ref-type="ref"} We identified relevant articles by systematically searching EMBASE.COM and MEDLINE (via OvidSP) from inception to 29 November 2013. We used the following abbreviated search strategy: "children" AND "pharmacoepidemiology" AND "comparative studies". Details of the full search strategy are included in [Appendix 1](#pds4041-supitem-0001){ref-type="supplementary-material"}. The computer‐based searches were conducted by a biomedical information specialist (WB), and were limited to human research without language limitations. One reviewer (OO) manually searched the bibliographies of relevant articles for additional relevant studies.

Study selection {#pds4041-sec-0008}
---------------

All observational studies with the main objective to quantify the association between a drug exposure(s) and the occurrence of adverse drug reaction(s) in children and adolescents (≤18 years of age) were eligible for inclusion in the review. Studies that included both children and adults were also retained. Drug exposures concerned all medicinal products including vaccines, applied either systemically or locally, and adverse drug reactions (ADRs) concerned all clinical events described as adverse outcomes to an individual (or combination of) drug(s) and/or vaccine(s).

We excluded RCTs and observational studies that evaluated drug safety signal detection in spontaneous reporting systems, compliance rates to medicinal treatments, incidence or prevalence of ADRs or other diseases within a defined population, teratogenic effects of drug exposure in pregnancy or through breast milk, medication errors, accidental and intentional poisoning, drug abuse, management of ADRs or other diseases, pharmacogenomics, pharmacoeconomics, health services utilization, environmental exposures or herbal treatments. We excluded case series, case reports, abstracts, letters, duplicate studies, preliminary publications or reviews. Only studies published in English were retained for the analysis.

All titles and abstracts were initially screened by one reviewer (OO) and full texts of potentially relevant articles were retrieved. A second reviewer (FK), blinded to the initial assessment, independently screened a sample of abstracts that comprised all abstracts retained plus a random selection of abstracts rejected by the first reviewer. Any disagreements between the two reviewers were examined by a third reviewer (G\'tJ). Full texts retained through this process were independently screened by two reviewers (OO and JD), disagreements were examined by a third reviewer (CF).

Data collection {#pds4041-sec-0009}
---------------

We developed a standardized form that was tested on 10 randomly selected papers, and was modified accordingly.

Data collected from each study pertained to journal impact factor (measured in 2013), study design, study period, type of data, study population, exposure, outcome, statistical analysis and results. We used country of corresponding author as a proxy for study setting. In the absence of information regarding study design, designs were classified based on data reviewers\' judgment. Case control studies included those studies that applied the nested case control design. Type of data implied primary versus secondary data (i.e. 'large' datasets like 'primary care (prescription) data', 'outpatient (pharmacy) dispensing data' and 'claims data'). The age of the study population was categorized according to guidelines defined by the International Conference on Harmonization (ICH)[11](#pds4041-bib-0011){ref-type="ref"}: newborns (0--27 days), infants and toddlers (28 days--23 months), children (2--11 years) and adolescents (12--18 years). We used the term drug to refer to small molecules as opposed to vaccines. Exposures and outcomes were classified as rare based on authors\' definitions. For the sources of exposure data, inpatient dispensing data included electronic prescription data for hospitalized patients, medical charts at the clinic implied paper charts, outpatient dispensing data implied pharmacy dispensing records, and registry included those that recorded information on vaccination and drug use. To assess whether follow‐up was long enough to observe the outcomes of interest in cohort studies, we applied the following minimum time intervals from drug exposure: fever---1 day, other acute events---2 weeks, cancer and other chronic (i.e. neurological and psychiatric) events---5 years. The full data extraction form is given in [Appendix 2](#pds4041-supitem-0001){ref-type="supplementary-material"}.

Both drugs and vaccines were mapped to the World Health Organization‐Anatomical Therapeutic Chemical (WHO‐ATC) classification (second or fifth level codes). The outcomes were mapped to the main divisions of the International Classification of Diseases (ICD), ninth edition.

Two reviewers (OO and JD) independently collected data from all full text articles. Discrepancies were discussed with three senior reviewers (FK, DW and CF).

In order to check for the impact of the Best Pharmaceuticals for Children Act (BPCA) which was introduced in the US in 2002,[3](#pds4041-bib-0003){ref-type="ref"} we compared the number of pediatric studies published before and after its introduction. We compared pediatric studies to all the published studies (i.e. pertaining to the general population).

Data analysis {#pds4041-sec-0010}
-------------

All continuous variables were described using medians (first \[Q1\]--third \[Q3\] quartiles) and categorical variables were summarized using counts and percentages. We performed hypothesis testing using the Mann--Whitney *U* test for continuous variables and Pearson chi‐square, Fischer\'s exact test or Z test for categorical variables. Analysis was performed by utilizing Statistical Package for the Social Sciences (SPSS) version 21.

Results {#pds4041-sec-0011}
=======

The search strategy yielded 4825 unique records after de‐duplication (Figure [1](#pds4041-fig-0001){ref-type="fig"}). After screening titles and abstracts, we retained 301 articles (inter‐reviewer concordance 90%) and after full text review, we retained 268 for analysis (inter‐reviewer concordance 92%).

![Flow chart depicting the selection of relevant papers](PDS-25-861-g001){#pds4041-fig-0001}

General characteristics of the studies {#pds4041-sec-0012}
--------------------------------------

The 268 retained studies were published from 1979 to 2013. In Figure [2](#pds4041-fig-0002){ref-type="fig"}, we compare the 268 studies to the total number (30,098) of studies (pertaining to the general population) published during the same period. After 2002, the number of pediatric studies steadily increased, more studies (196 \[73.1%\]) were published during the 10‐year period from 2003 to 2013, compared to studies (72 \[26.9%\]) published during the preceding 24‐year period.

![Number of pharmacoepidemiological safety studies in children. Note: In order to retrieve all published pharmacoepidemiological safety studies that investigated the general population, we applied the same search algorithm that was utilized for studies in children except that for the former, we did not limit to the pediatric population; papers that were published in 2013 are those papers that were indexed in Embase and Medline as at 29 November](PDS-25-861-g002){#pds4041-fig-0002}

Most studies originated from North America (154 \[57.5%\]) or Europe (92 \[34.3%\]) and most studies (147 \[54.9%\]) assessed only drugs. Only three studies (1.1%) evaluated both drugs and vaccines, the studies investigated only children for the effect of the following drug classes (WHO‐ATC second level): 'corticosteroids for systemic use', 'ántibacterials for systemic use', 'cough and cold preparations' and 'anti‐inflammatory and anti‐rheumatic products'. The investigated vaccines were 'diphtheria--tetanus--pertussis', 'measles--mumps--rubella'*,* 'hepatitis B virus'*,* 'óral polio virus' and 'inactivated polio virus'*.*

Considering 268 studies, 183 (68.3%) included only children, the remainder studied both children and adults. Studies on drug safety evaluation included most frequently children aged 2--11 years while vaccine safety studies were most frequently conducted in infants and toddlers (Table [1](#pds4041-tbl-0001){ref-type="table-wrap"}). Only 14 studies (5.0%) included preterm newborns.

###### 

General characteristics for 268 pharmacoepidemiological studies that evaluated the safety of drugs and vaccines in children (≤18 years)

                                                                                                                                             Total (268)        Type of exposure investigated                     
  ------------------------------------------------------------------------------------------------------------------------------------------ ------------------ ------------------------------- ----------------- ------------
  **Continent of the corresponding author**                                                                                                                                                                       0.90
  North America                                                                                                                              154 (57.5)         83 (56.5)                       70 (59.3)         
  Europe                                                                                                                                     92 (34.3)          52 (35.4)                       39 (33.1)         
  Asia                                                                                                                                       12 (4.5)           7 (4.8)                         4 (3.4)           
  Others                                                                                                                                     10 (3.7)           5 (3.4)                         5 (4.2)           
  **Type of journal**                                                                                                                                                                                             0.07
  Pediatric specialty                                                                                                                        88 (32.8)          45 (30.6)                       42 (35.6)         
  Pharmacology/pharmacoepidemiology                                                                                                          30 (11.2)          21 (14.3)                       7 (5.9)           
  General medical[\*](#pds4041-note-0004){ref-type="fn"}                                                                                     39 (14.6)          17 (11.6)                       22 (18.6)         
  Others[†](#pds4041-note-0005){ref-type="fn"}                                                                                               111 (41.4)         64 (43.5)                       47 (39.8)         
  **2013 two‐year journal impact factor**                                                                                                    3.8 (3.1--5.3)     3.7 (2.6--5.5)                  4.6 (3.6--5.6)    **0.01**
  Missing data                                                                                                                               18 (6.7)           14 (9.5)                        4 (3.4)           
  **Funding sources**                                                                                                                                                                                             **\<0.01**
  Public                                                                                                                                     96 (35.8)          38 (25.9)                       55 (46.6)         
  Private                                                                                                                                    47 (17.5)          25 (17.0)                       22 (18.6)         
  Public and private                                                                                                                         26 (9.7)           14 (9.5)                        12 (10.2)         
  No funding                                                                                                                                 7 (2.6)            5 (3.4)                         2 (1.7)           
  Funding not reported                                                                                                                       92 (34.3)          65 (44.2)                       27 (22.9)         
  **Study period, years**                                                                                                                    3.7 (1.7--8.9)     4.6 (1.7--9.0)                  3.2 (1.7--7.0)    0.31
  Missing data                                                                                                                               14 (5.2)           11 (4.1)                        3 (1.1)           
  **Study population** [‡](#pds4041-note-0006){ref-type="fn"}                                                                                                                                                     
  **Age at inclusion**                                                                                                                                                                                            
  Minimum age, years                                                                                                                         0.1 (0--2.0)       0.1 (0--3.0)                    0.2 (0--1.0)      0.51
  Maximum age, years                                                                                                                         16.5 (2.0--21.0)   18.0 (13.5--63.5)               5.0 (1.5--17.0)   **\<0.01**
  **Preterm newborns**                                                                                                                                                                                            **\<0.01**
  Exclusively                                                                                                                                9 (3.3)            9 (6.1)                         0                 
  Partially                                                                                                                                  5 (1.9)            4 (2.7)                         1 (0.8)           
  No                                                                                                                                         254 (94.8)         134 (91.2)                      117 (99.2)        
  **Term newborns (0--27 days)**                                                                                                             106 (39.5)         61 (41.5)                       44 (37.3)         0.49
  **Infants/toddlers (28 days--23 months)**                                                                                                  168 (62.9)         80 (54.4)                       86 (72.9)         **\<0.01**
  **Children (2--11 years)**                                                                                                                 202 (75.4)         117 (80.0)                      82 (69.5)         0.05
  **Adolescents (12--18 years)**                                                                                                             157 (58.9)         110 (74.8)                      45 (38.1)         **\<0.01**
  **Mixed (adults and children)**                                                                                                            85 (31.7)          67 (45.6)                       18 (15.3)         **\<0.01**
  **WHO‐ATC level of investigated exposure (reported name)** [§](#pds4041-note-0007){ref-type="fn"}                                                                                                               **\<0.01**
  Fifth level (specific compound)                                                                                                            203 (75.7)         87 (59.2)                       116 (98.3)        
  Second,third or fourth level (class)                                                                                                       51 (19.0)          51 (34.7)                       0                 
  Both                                                                                                                                       14 (5.2)           9 (6.1)                         2 (1.7)           
  **Number of specific compounds (WHO‐ATC fifth level) that were investigated** [¶](#pds4041-note-0008){ref-type="fn"}                                                                                            0.14
  1                                                                                                                                          137 (63.1)         54 (56.3)                       81 (68.6)         
  2                                                                                                                                          35 (16.1)          20 (20.8)                       15 (12.7)         
  ≥3                                                                                                                                         45 (20.7)          22 (22.9)                       22 (18.6)         
  **Number of drug/vaccine classes (WHO‐ATC second, third or fourth level) that were investigated** [∥](#pds4041-note-0009){ref-type="fn"}                                                                        0.27
  1                                                                                                                                          48 (73.8)          45 (75.0)                       1 (50.0)          
  2                                                                                                                                          8 (12.3)           7 (11.7)                        1 (50.0)          
  ≥3                                                                                                                                         9 (13.8)           8 (13.3)                        0                 

Note: Missing data is presented for only instances where it constitutes greater than 5%.

The p‐values in bold format are statistically significant. NA = not applicable.

Studies assessing drugs (147) or vaccines (118) exclusively do not add up to the total number of studies (268) because three studies that investigated both drugs and vaccines are not presented in the table.

Refers to journals that publish wide variety of medical topics (irrespective of specialty).

Journals that do not fit into any of the specified categories i.e. PLOS ONE.

For the age distributions, the proportions do not add up to 100% because some studies included multiple age categories.

World Health Organization‐Anatomic Therapeutic Chemical.

The proportions are based on only those studies that investigated specific compounds either exclusively or in combination with drug/vaccine class.

The proportions are based on only those studies that investigated drug/vaccine class either exclusively or in combination with specific compounds.

The median impact factor of the journals in which the studies were published was 3.8 (3.1--5.3). As seen in Table [1](#pds4041-tbl-0001){ref-type="table-wrap"}, vaccine‐only studies (4.6 \[3.6--5.6\]) were published in higher impact journals than drug‐only studies (3.7 \[2.6--5.5\]) (Mann--Whitney *U p*‐value 0.01). Few studies were published in pediatric (88 \[32.8%\]) or pharmacoepidemiological specialty (30 \[11.2%\]) journals. Only 14 studies (17.5%) were privately funded, vaccine studies were more frequently publicly funded but for a large proportion the type of funding was unknown. Regardless of the type of exposure that was investigated, privately funded studies (journal impact factor = 3.5; 3.1--5.3) were of lower impact than studies receiving public funding (journal impact factor = 5; 3.5--7.8) (Mann--Whitney *U p*‐value \< 0.01).

Methodology of the studies {#pds4041-sec-0013}
--------------------------

From the 268 studies, 202 (75.4%) reported the study design(s) and for the remaining study design was classified according to the reviewers\' judgment. Cohort studies were the most common (174 \[64.9%\]), and 23 studies (8.6%) applied more than one design. Case‐only designs were seldom used: the self‐controlled case series (SCCS) design was utilized in only 30 studies (11.2%), to evaluate vaccine‐related outcomes exclusively. Similarly, case‐crossover studies were few (4 \[1.5%\]).

In most studies (196 \[73.1%\]), data collection was retrospective. Prospective studies (88 \[32.8%\]) were usually cohort studies that used mainly primary data (56 \[63.6%\]) and were smaller than studies with retrospective data. Secondary data was utilized for both drugs and vaccines and concerned 183 studies (68.3%). Studies using secondary data had larger sample sizes than studies using primary data collection. Exposure and outcome data were collected from mainly medical charts ((85 \[31.7%\]) and (122 \[45.5%\]) respectively) followed by claims data and primary care medical or dispensing data (Table [2](#pds4041-tbl-0002){ref-type="table-wrap"}).

###### 

Methodology of 268 pharmacoepidemiological studies that evaluated the safety of drugs and vaccines in children (≤18 years)

                                                                                               Total (268)                 Type of exposure investigated                                 
  -------------------------------------------------------------------------------------------- --------------------------- ------------------------------- ----------------------------- ------------
  **Design** [\*](#pds4041-note-0013){ref-type="fn"}                                                                                                                                     
  Cohort                                                                                       174 (64.9)                  114 (77.6)                      60 (50.8)                     **\<0.01**
  Case control                                                                                 73 (27.2)                   31 (21.1)                       39 (33.1)                     **0.03**
  Self‐controlled case series                                                                  30 (11.2)                   0                               30 (25.4)                     NA
  Case crossover                                                                               4 (1.5)                     3 (2.0)                         1 (0.8)                       0.42
  Others[†](#pds4041-note-0014){ref-type="fn"}                                                 14 (5.2)                    6 (4.1)                         8 (6.8)                       0.33
  **Mode of data collection** [‡](#pds4041-note-0015){ref-type="fn"}                                                                                                                     
  Retrospective                                                                                177 (66.0)                  96 (65.3)                       80 (67.8)                     0.66
  Prospective                                                                                  69 (25.7)                   41 (27.9)                       26 (22.0)                     0.27
  Both                                                                                         19 (7.1)                    10 (6.8)                        9 (7.6)                       0.80
  Unclear[§](#pds4041-note-0016){ref-type="fn"}                                                3 (1.1)                     0                               3 (2.5)                       NA
  **Type of data**                                                                                                                                                                       0.11
  Primary                                                                                      58 (21.6)                   38 (25.9)                       18 (15.3)                     
  Secondary                                                                                    183 (68.3)                  95 (64.6)                       87 (73.7)                     
  Mixed                                                                                        27 (10.1)                   14 (9.5)                        13 (11.0)                     
  **Source of (collection method for) exposure data** [¶](#pds4041-note-0017){ref-type="fn"}                                                                                             
  Primary care (prescription) data                                                             27 (10.1)                   14 (9.5)                        12 (10.2)                     0.85
  Outpatient (pharmacy) dispensing data                                                        19 (7.1)                    7 (4.8)                         12 (10.2)                     0.09
  Inpatient dispensing data                                                                    21 (7.8)                    18 (12.2)                       2 (1.7)                       **\<0.01**
  Paper medical chart                                                                          85 (31.7)                   54 (36.7)                       29 (24.6)                     **0.03**
  Claims data                                                                                  55 (20.5)                   25 (17.0)                       30 (25.4)                     0.09
  Registry                                                                                     35 (13.1)                   16 (10.9)                       19 (16.1)                     0.21
  Self‐report questionnaire                                                                    12 (4.5)                    7 (4.8)                         5 (4.2)                       0.82
  Telephone call                                                                               13 (4.9)                    5 (3.4)                         8 (6.8)                       0.20
  Face to face interview                                                                       17 (6.3)                    6 (4.1)                         10 (8.5)                      0.14
  Others[∥](#pds4041-note-0018){ref-type="fn"}                                                 40 (14.9)                   15 (10.2)                       25 (21.2)                     **0.01**
  Unclear[\*\*](#pds4041-note-0019){ref-type="fn"}                                             13 (4.9)                    7 (4.8)                         6 (5.1)                       0.91
  **Source of (collection method for) outcome data** [††](#pds4041-note-0020){ref-type="fn"}                                                                                             
  Primary care data                                                                            29 (10.8)                   14 (9.5)                        15 (12.7)                     0.41
  Paper medical charts                                                                         122 (45.5)                  66 (44.9)                       53 (44.9)                     1.00
  Institution, administrative or electronic heath records                                      60 (22.4)                   23 (15.6)                       37 (31.4)                     **\<0.01**
  Claims data                                                                                  71 (26.5)                   32 (21.8)                       38 (32.2)                     0.06
  Registry                                                                                     38 (14.2)                   21 (14.3)                       17 (14.4)                     0.98
  Self‐report questionnaire                                                                    25 (9.3)                    13 (8.8)                        12 (10.2)                     0.70
  Telephone call                                                                               13 (4.9)                    8 (5.4)                         5 (4.2)                       0.65
  Face to face interview                                                                       12 (4.5)                    6 (4.1)                         6 (5.1)                       0.70
  Others[‡‡](#pds4041-note-0021){ref-type="fn"}                                                32 (11.9)                   18 (12.2)                       14 (11.9)                     0.94
  Unclear[§§](#pds4041-note-0022){ref-type="fn"}                                               4 (1.5%)                    3 (2.0)                         1 (0.8)                       0.42
  **Size of the study population per design**                                                                                                                                            
  **Fixed cohort**                                                                                                                                                                       
  Exposed, number of participants                                                              2050 (103--34 544)          283 (51--12 432)                44 001 (4009--278 624)        **\<0.01**
  Unexposed, number of participants                                                            1073 (74--27 417)           372 (58--8533)                  24 175 (1215--227 288)        0.67
  Missing data                                                                                 18 (32.2)                   6 (6.2)                         12 (30.8)                     
  **Dynamic cohort \[person‐years(PY)\]**                                                                                                                                                
  Exposed PY                                                                                   92 835 (11 931--731 043)    62 383 (3600--416 018)          123 287 (14 708--1 220 006)   0.56
  Unexposed PY                                                                                 362 142 (9235--1 315 038)   162 622 (5485--1 728 969)       535 375 (17 496--1 298 601)   0.90
  **Case--control**                                                                                                                                                                      
  Cases                                                                                        189 (68--467)               79 (30--532)                    252 (133--452)                **0.03**
  Number of controls per case                                                                  2.2 (1.1--4.2)              2.1 (1.0--4.4)                  2.8 (2.0--4.1)                0.24
  **SCCS and Case Crossover, number of participants**                                          402 (168--1380)             NA                              369 (173--1334)               NA
  Missing data                                                                                 5 (14.7)                    0                               5 (16.1)                      
  **Control of confounding** [¶¶](#pds4041-note-0023){ref-type="fn"}                                                                                                                     
  Matching                                                                                     98 (36.6)                   43 (29.3)                       53 (44.9)                     **\<0.01**
  Stratification                                                                               103 (38.4)                  36 (24.5)                       66 (55.9)                     **\<0.01**
  Multivariate modeling adjustment                                                             138 (51.5)                  75 (51.0)                       60 (50.8)                     0.97

Note: Missing data is presented for only instances where it constitutes greater than 5%.

The p‐values in bold format are statistically significant. NA = not applicable.

Studies assessing drugs (147) or vaccines (118) exclusively, do not add up to the total number of studies (268) because three studies that investigated both drugs and vaccines are not presented in the table.

The proportions do not add up to 100% because some studies applied multiple designs.

Includes study designs that are not listed, i.e. case‐time‐control.

The proportions do not add up to 100% because some studies applied multiple data collection modes.

Implies that there was inadequate information to determine if data collection was done prospectively or retrospectively.

The proportions do not add up to 100% because some studies applied multiple sources (or collection modes for) exposure data.

Includes data sources (or collection methods) that are not specified e.g. maternal and child health handbook.

Implies that there was inadequate information to determine the source of (or collection mode for) the exposure data.

The proportions do not add up to 100% because some studies applied multiple sources (or collection modes for) outcome data.

Includes data sources (or collection methods) that are not specified, e.g. maternal and child health handbook.

Implies that there was inadequate information to determine the source of (or collection mode for) the outcome data.

The proportions do not add up to 100% because some studies applied methods to control confounding.

Out of 147 studies that evaluated drugs exclusively, 87 (59.2%) assessed only exposures to specific compounds (i.e. amoxicillin), 51 (34.7%) evaluated exposures to a specific drug class (i.e. 'antibacterials for systemic use'), only 9 (6.1%) assessed both specific compound and drug class. Regarding the 96 studies that assessed specific compounds, 54 (56.3%) investigated only one compound, 20 (20.8%) assessed two compounds and 22 (22.9%) assessed three or more. Given the 60 studies that assessed drug class, 45 (75.0%) investigated only one class, 7 (11.7%) assessed two classes and 8 (13.3%) investigated three or more. Fourteen studies (23.3%) evaluated 'antibacterials for systemic use', 10 (16.7%) assessed psychoanaleptics and 7 (11.7%) assessed psycholeptics. Considering 14 drug safety studies that included preterm newborns, 'antibacterials for systemic use' were evaluated in 3 (21.4%) and 'corticosteroids for systemic use' in 2 (14.3%). For details of studied drug by age, see electronic [Supporting Information](#pds4041-supitem-0001){ref-type="supplementary-material"}.

Across the 150 studies that assessed drugs whether exclusively or with vaccines, a total of 291 unique exposures representing 39 unique classes (WHO‐ATC second level) were investigated. Psychoanaleptics (53 \[18.2%\]) were the commonest, followed by 'antibacterials for systemic use' (40 \[13.7%\]) and psycholeptics (38 \[13.1%\]). For further details, see Table [3](#pds4041-tbl-0003){ref-type="table-wrap"}.

###### 

Twenty most frequently investigated drug classes across the 150 studies that investigated drugs (whether exclusively or with vaccines)

  Drug class (WHO‐ATC second level)[\*](#pds4041-note-0024){ref-type="fn"}   Code   *N* (%)[†](#pds4041-note-0025){ref-type="fn"}
  -------------------------------------------------------------------------- ------ -----------------------------------------------
  **Psychoanaleptics**                                                       N06    53 (18.2)
  **Antibacterials for systemic use**                                        J01    40 (13.7)
  **Psycholeptics**                                                          N05    38 (13.1)
  **Antineoplastic agents**                                                  L01    30 (10.3)
  **Anti‐inflammatory and anti‐rheumatic products**                          M01    18 (6.2)
  **Anti‐epileptics**                                                        N03    12 (4.1)
  **Corticosteroids for systemic use**                                       H02    11 (3.8)
  **Analgesics**                                                             N02    10 (3.4)
  **Contrast media**                                                         V08    8 (2.7)
  **Immunosuppresants**                                                      L04    7 (2.4)
  **Anesthetics**                                                            N01    6 (2.1)
  **Antihistamines for systemic use**                                        R06    6 (2.1)
  **Antihemorrhagics**                                                       B02    5 (1.7)
  **Pituitary and hypothalamic hormones and analogues**                      H01    5 (1.7)
  **Antivirals for systemic use**                                            J05    5 (1.7)
  **Drugs for obstructive airway diseases**                                  R03    4 (1.4)
  **Cardiac therapy**                                                        C01    3 (1.0)
  **Cough and cold preparations**                                            R05    3 (1.0)
  **Drugs for functional gastrointestinal disorders**                        A03    2 (0.7)
  **Agents acting on the renin‐angiotensin system**                          C09    2 (0.7)

World Health Organization‐Anatomic Therapeutic Chemical classification.

Proportion is based on the total number (291) of unique drug exposures that were investigated.

Considering drug evaluations exclusively, only three studies (2.0%) assessed the effect of rarely used drugs (i.e. ciprofloxacin) and only 30 (20.0%) assessed dose‐effects.

Altogether, 588 outcomes were evaluated with a median of 1([1](#pds4041-bib-0001){ref-type="ref"}, [2](#pds4041-bib-0002){ref-type="ref"}) outcome per study; 36 studies (13.4%) did not state the outcome definition. Most events (68 \[39.5%\]) were acute, and defined as symptoms, signs or ill‐defined conditions (i.e. diarrhea) (Figure [3](#pds4041-fig-0003){ref-type="fig"}). Rare outcomes (i.e. Stevens--Johnson syndrome) were evaluated in only 17 studies (6.3%). Expert validation of the outcomes was frequent (172 \[64.2%\]) but only in 46 of those (26.7%) the experts were blinded to exposure.

![Distribution of papers according to the main divisions of the International Classification of diseases (ninth edition), and type of exposure. Note: 'Certain conditions originating in the perinatal period' includes 'Other conditions originating in the perinatal period' (764--779) which does not include maternal causes, i.e. Necrotizing enterocolitis (777.5); 'Injury and poisoning' includes 'unspecified adverse effect of drug medicinal and biological substance not elsewhere classified' (995.2)](PDS-25-861-g003){#pds4041-fig-0003}

Out of 174 cohort studies, the follow‐up time was inadequate to observe the investigated outcomes in 76 (43.7%).

Only 27 studies (10.1%) reported sample size or power calculations. Cohort studies were the largest unlike SCCS and case crossover studies which included few participants. Most studies (229 \[85.4%\]) adjusted for confounding either by stratification (mainly vaccine safety studies), matching or by multivariate modeling (mainly drug safety studies).

Only 133 studies (49.6%) specified a primary objective and 129 studies (48.1%) reported at least one statistically significant result. This proportion increased to 59.0% when only 183 child‐specific studies were considered. Most studies with significant statistical results (97 \[75.2%\]) were published after 2002. Among the 75 child‐specific studies that did not present any statistically significant result, 41 (54.7%) did not discuss lack of power.

Discussion {#pds4041-sec-0014}
==========

We have conducted a systematic review to assess the characteristics of pediatric pharmacoepidemiological safety studies that were published over 34 years, while aiming to identify areas for improvement of these much needed studies. The review also highlights differences in drug versus vaccine pediatric studies. Some previous reviews have summarized evidence regarding specific drug or vaccine safety issues that affect children[12](#pds4041-bib-0012){ref-type="ref"}, [13](#pds4041-bib-0013){ref-type="ref"}, [14](#pds4041-bib-0014){ref-type="ref"}, [15](#pds4041-bib-0015){ref-type="ref"} while others have focused on specific methodological aspects of pediatric pharmacoepidemiology[16](#pds4041-bib-0016){ref-type="ref"}, [17](#pds4041-bib-0017){ref-type="ref"} but to the best of our knowledge no review has attempted to provide a general overview of these studies.

Our main findings are: the absolute number of pediatric pharmacoepidemiological safety studies is low; in 2012 only 33 studies concerned pediatrics compared to a total of 3197 published studies (data not presented but utilized in constructing Figure [2](#pds4041-fig-0002){ref-type="fig"}). Such studies are almost exclusively conducted in developed countries and receive very little private funding. Evaluated exposures concern few pharmaceuticals while investigating mainly intermediate clinical outcomes (signs/symptoms). As areas of improvement we recommend better global spread, interaction between pharmacoepidemiologists evaluating drugs and vaccines to apply designs more broadly, more focus and funding of such studies, and collaboration between investigators so that larger size studies can be conducted that may have enough power to study the rarer and potentially more serious safety issues.

Although paper medical charts may be regarded as the gold standard source of patient information electronic health records and claims data comprise vast amounts of routine care information that can be readily utilized for pharmacoepidemiological safety studies, as demonstrated by several authors.[18](#pds4041-bib-0018){ref-type="ref"}, [19](#pds4041-bib-0019){ref-type="ref"}, [20](#pds4041-bib-0020){ref-type="ref"}, [21](#pds4041-bib-0021){ref-type="ref"} More extensive use of such data may be needed to overcome the problem of inadequate follow‐up for many cohort studies as demonstrated in this review, especially if this is related to the high costs that is associated with long follow‐up time in some prospective studies utilizing primary data collection. Generally, the potential of secondary data has been recognized by FDA in Sentinel,[22](#pds4041-bib-0022){ref-type="ref"} by Health Canada in their CNODES project[23](#pds4041-bib-0023){ref-type="ref"} and in Europe by the GRIP consortium and other projects.[24](#pds4041-bib-0024){ref-type="ref"} We should now focus the potential of these powerful resources on pediatric studies specifically in order to quickly fill the existing gap in knowledge of drug use.

The number of pediatric safety studies started increasing steadily after 2002, following the introduction of the 'Best Pharmaceuticals for children Act' (BPCA).[3](#pds4041-bib-0003){ref-type="ref"} Under the BPCA, the US National Institutes of Health sponsored several pharmacoepidemiological studies in children.[25](#pds4041-bib-0025){ref-type="ref"} The pediatric regulation was introduced in the European Union in 2007, perhaps explaining the even steeper increase in the number of pediatric studies that is observed after 2007 (Figure [2](#pds4041-fig-0002){ref-type="fig"}). The predominance of US and EU studies may be explained partially by these legislations but also by the number of epidemiologists and data resources. Whatever the explanation may be, this review points to a large public health need for more human capacity building and studies in many children that live in other parts of the world, particularly lower and middle income countries. From a publication and academic perspective it should be noted that the studies were published mostly in more general journals and the impact factors were well above the median in the pharmacology field.

Where should funding for such studies come from? Generally, studies relying on secondary data are affordable. In this review we observed that few studies were privately funded. We recommend that the politicians who passed the BPCA and other legislations to stimulate generation of efficacy data in children see the potential of pharmacoepidemiology rather than clinical trials to generate safety data and oblige long‐term postmarketing studies in children for newly marketed drugs specifically. Studies on off‐patent drugs that are frequently used in children should be investigated through public funding in both developing and developed countries.

Almost half of the evaluated drugs belong to only three classes (Table [3](#pds4041-tbl-0003){ref-type="table-wrap"}): anti‐infectives, psychoanaleptics and psycholeptics. Although anti‐infectives are often prescribed in pediatrics across all age groups, psychoanaleptics and psycholeptics represent a minority of drug exposure in children.[26](#pds4041-bib-0026){ref-type="ref"} However, these drugs have been surrounded by specific safety issues.[27](#pds4041-bib-0027){ref-type="ref"}, [28](#pds4041-bib-0028){ref-type="ref"} Specifically, psychoanaleptics (i.e. atomoxetine and methylphenidate) were commonly mentioned in pediatric case reports submitted to FAERS between 2004 and 2011,[29](#pds4041-bib-0029){ref-type="ref"} probably reflecting its increased use and high risk of toxicity, notably cardiovascular toxicity, as demonstrated by several authors in our review.[27](#pds4041-bib-0027){ref-type="ref"}, [28](#pds4041-bib-0028){ref-type="ref"}, [30](#pds4041-bib-0030){ref-type="ref"}, [31](#pds4041-bib-0031){ref-type="ref"}, [32](#pds4041-bib-0032){ref-type="ref"}

Very few studies evaluated rare drug exposures possibly because such studies would not have been adequately powered to detect an association. Specifically, in preterm newborns, the investigated drugs (i.e. sildenafil and morphine) are possibly associated with serious safety issues;[33](#pds4041-bib-0033){ref-type="ref"}, [34](#pds4041-bib-0034){ref-type="ref"}, [35](#pds4041-bib-0035){ref-type="ref"} however, these studies could not confirm safety associations possibly because of their limited sample size. Inadequate sample size may account for the lack of at least one statistically significant result in 41% of the child‐specific studies, even if majority of these studies did not discuss lack of power. Size issues may be addressed by implementing case‐only (i.e. SCCS) designs.[36](#pds4041-bib-0036){ref-type="ref"} In our review, few studies applied case‐only analysis essentially to evaluate vaccine safety. However, case‐only designs present strengths that are suited for the drug utilization patterns and characteristics of outcomes in children.[37](#pds4041-bib-0037){ref-type="ref"}, [38](#pds4041-bib-0038){ref-type="ref"} Further, multi‐site data pooling may be necessary to acquire adequate power to study rare events in children.[39](#pds4041-bib-0039){ref-type="ref"}, [40](#pds4041-bib-0040){ref-type="ref"} International collaboration on a global scale may be required; this is the main aim of the Global Research in Pediatrics (GRIP) project.

The strength of this review is the systematic assessment of pharmacoepidemiological safety studies in children, with broad inclusion criteria. Regarding limitations, we applied minimum follow‐up periods (to cohort studies) according to the type of investigated outcome; this may not have been accurate for some specific outcomes. Yet, standardization was necessary because the outcomes were numerous and highly heterogeneous. Also, the findings we have presented are based on published data reported by authors of the studies; therefore, if such reporting was incomplete and/or inaccurate, this may have impacted our findings. For example, several irrelevant drug exposures were assessed in neonates ([electronic Supporting Information](#pds4041-supitem-0001){ref-type="supplementary-material"}), like anti‐obesity preparations or antineoplastic drugs merely because authors stated that included pediatric population started at 0 years of age. Such imprecisions inevitably lead to erroneous conclusions. Also, we used country of corresponding author as a proxy for the study setting; by doing this, study setting for multi‐country database studies may not have been accurately captured. Further, we used the journal impact factor as a proxy for the quality of the studies that we reviewed; the limitations of this measure have been described in the literature.

Based on the reviewed literature, we conclude that there is a need to build global collaborative capacity and funding opportunities for pediatric pharmacoepidemiology because this is one of the most powerful ways to provide evidence of drug safety in children.
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